Sensitization of U937 leukemia cells to doxorubicin by the MG132 proteasome inhibitor induces an increase in apoptosis by suppressing NF-kappa B and mitochondrial membrane potential loss

BACKGROUND: The resistance of cancerous cells to chemotherapy remains the main limitation for cancer treatment at present. Doxorubicin (DOX) is a potent antitumor drug that activates the ubiquitin-proteasome system, but unfortunately it also activates the Nuclear factor kappa B (NF-кB) pathway leadi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortiz-Lazareno, Pablo César, Bravo-Cuellar, Alejandro, Lerma-Díaz, José Manuel, Jave-Suárez, Luis Felipe, Aguilar-Lemarroy, Adriana, Domínguez-Rodríguez, Jorge Ramiro, González-Ramella, Oscar, De Célis, Ruth, Gómez-Lomelí, Paulina, Hernández-Flores, Georgina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927225/
https://www.ncbi.nlm.nih.gov/pubmed/24495648
http://dx.doi.org/10.1186/1475-2867-14-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927225/
https://www.ncbi.nlm.nih.gov/pubmed/24495648
http://dx.doi.org/10.1186/1475-2867-14-13

Ejemplares similares